| Literature DB >> 33663778 |
Mark Hensey1, Richard A Brown2, Sudish Lal3, Janarthanan Sathananthan4, Jian Ye4, Anson Cheung4, Philipp Blanke4, Jonathon Leipsic4, Robert Moss4, Robert Boone4, John G Webb4.
Abstract
Growing clinical data support the use of transcatheter therapies for significant mitral valve disease. Currently, edge-to-edge repair is the transcatheter treatment of choice, but many anatomies are not suitable. Transcatheter mitral valve replacement offers several potential advantages over transcatheter repair, most notably a greater and more sustained reduction in mitral regurgitation post-implantation, but also potential disadvantages. To enable the successful treatment of mitral valve disease in a wide range of patients and anatomies, we require an armory of transcatheter devices, including transcatheter mitral valve replacement systems. CrownEntities:
Keywords: mitral; transcatheter; valve
Year: 2021 PMID: 33663778 DOI: 10.1016/j.jcin.2020.12.038
Source DB: PubMed Journal: JACC Cardiovasc Interv ISSN: 1936-8798 Impact factor: 11.195